A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
- Sponsor
- Sanofi
- Study ID
- NCT07484230
- Phase
- PHASE3
- Status
- Withdrawn
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Itepekimab (SAR440340) — DRUGPharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
- Placebo — DRUGPharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
Study Details
This is a randomized, multicenter, double-blind, Phase 3 study with 2 parallel groups. The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different dosing regimens of itepekimab monotherapy in Japanese participants aged 18 years or older with chronic rhinosinusitis with nasal polyp(s) (CRSwNP) who are not adequately controlled despite previous surgery and/or treatment with systemic corticosteroid(s) (SCS). The total study duration par participant is approximately 76 week, including: * A screening period for up to 4 weeks. * A randomized study intervention period for up to 52 weeks * A post-intervention safety follow-up for up to 20 weeks * The number of visits will be 9 site visits and 20 phone/home visits
Key Dates
- First listed
- Mar 20, 2026
- Start date
- May 8, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 20, 2027
- Completion
- Oct 10, 2028
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Itepekimab high doseSubcutaneous (SC) administration of Itepekimab high dose for 52 weeks
- Experimental: Itepekimab low doseSC administration of Itepekimab low dose for 52 weeks
Primary Outcome Measure
Change from baseline in the endoscopic NPS [ Time Frame: Baseline to Week 24 ]
Related Studies
- Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal PolyposisRecruiting · Montefiore Medical Center · The Bronx, New York
- 3D Printing to Improve Nasal Irrigation OutcomeRecruiting · Ohio State University · Columbus, Ohio
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyPHASE2 · Enrolling By Invitation · Sanofi · La Jolla, California